Pulling SEC filings + quote and writing the call…

GENWORTH FINANCIAL INC
Next earnings Jul 28, 2026 · consensus $0.10 EPS
Last earnings +0.0% on 2026-05-05
Cheap on price/sales with aggressive buybacks, but earnings quality is deteriorating and ROE is anemic — a value trap risk.
Price $9.29 · current
Middling fundamentals and a rich price (~59% above fair value) leave little margin of safety — a wait-and-see.
Genworth is a tale of two stories sitting at an uncomfortable middle. The headline valuation looks compelling: 0.5x P/S, a $3.60B market cap against $8.75B of book equity (roughly 0.41x P/B implied), and management is shrinking the share count aggressively — shares outstanding fell 7.5% YoY and the company spent $247M on buybacks in FY2025 (up 30.7%). Retained earnings are climbing (+15.2% to $1.68B), and operating cash flow rebounded sharply to $327M (+271.6%). For a sub-$10 stock trading well below book, that buyback cadence is the most tangible bull case.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $7.82B | $7.50B | $7.49B | $7.29B | $7.30B |
| Gross profit | — | — | — | — | — |
| Operating income | $474M | $818M | $41.0M | — | — |
| Net income | $850M | $916M | $76.0M | $299M | $223M |
| Diluted EPS | $1.65 | $1.79 | $0.16 | $0.68 | $0.54 |
| Net margin | 10.9% | 12.2% | 1.0% | 4.1% | 3.1% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Annual meeting vote results; directors elected and routine governance items approved
Q1 2026 10-Q: ongoing buybacks, Enact persistency easing as rates decline
Q1 2026 earnings release; Enact steady, buyback program continuing
FY2025 10-K: Enact loss ratio jumped to 11% from 4%; $247M buybacks, shares -7.5%
FY2025 results: net income $223M down 25% YoY, EPS $0.54 vs $0.68
Interim financial disclosure ahead of Q4 release; likely Enact capital/special-item update
Q3 2025 10-Q filing with quarterly financials and Enact segment update
Q3 2025 earnings; Enact reserve releases moderating as loss ratio normalizes
Q2 2025 10-Q; mortgage insurance in-force grew modestly amid rate volatility
Sources: SEC EDGAR (CIK 0001276520, latest 10-Q filed 2026-05-06) · EODHD · analysis by claude-code · as of 6/25/2026, 1:26:22 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 2 sales
| 2026-05-27 | McInerney Thomas J President and CEO; Director | Gift | 200K | |
| 2026-05-22 | McInerney Thomas J President and CEO; Director | Sell | 100K @ $9.27 | $927K |
| 2026-05-22 | RESTREPO ROBERT P JR Director | Sell | 50.0K @ $9.12 | $456K |
| 2026-05-21 | Taylor Morris C. EVP & CIO | Exercise | 21.5K | |
| 2026-05-21 | Taylor Morris C. EVP & CIO | Tax | 6.48K @ $9.19 | $59.5K |
| 2026-05-20 | Van Wyk Steven C. Director | Award | 32.1K @ $9.03 | $290K |
| 2026-05-20 | Smith Ramsey D. Director | Award | 18.3K @ $9.03 | $165K |
| 2026-05-20 | Sarsynski Elaine A Director | Award | 32.1K @ $9.03 | $290K |
| 2026-05-20 | RESTREPO ROBERT P JR Director | Award | 18.3K @ $9.03 | $165K |
Source: EODHD. Yield = trailing-12-month dividends ÷ price.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1043 tracked peers · median
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.